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In the majority of patients admitted to an Intensive Care Unit with acute respiratory failure (ARF), the aetiology
for ARF is quite evident. In a minority of patients no obvious aetiology is apparent at presentation. In this group a
previously unrecognized sleep-related breathing disorder (SRBD) may be the cause of the ARF. In spite of clinical
suspicion SRBD remains infrequently diagnosed in ARF also because the technology necessary for this type of
diagnosis (polysomnography) is usually unavailable in Intensive Care Units.
The aim of this study was to evaluate the utility of portable polysomnography system (PSGp) in a group of
patients with ARF of unclear aetiology and with a clinical suspicion of SRBD. We studied a selected group of 14
patients (eight males, six females) admitted to an Intermediate Intensive care unit with varying degree of acute
respiratory failure. Mean (SD) age was 57 (13) years, pH 728 (004), PaO2 56 (07) kPa), PaO2 (88 (16) kPa), Body
mass index 427 (96) kg m72. The patients had no history of skeletal, neuromuscular or cardiovascular disease.
None of them had a history of overt chronic lung diseases or had obvious respiratory tract infections. They were
submitted to cardiac and respiratory functional evaluation and to nightly PSGp (VITALOG HMS 5000,
Respironics Inc., Redwood City, CA, U.S.A.) which was performed in an intermediate intensive care unit.
Ten subjects had obstructive sleep apnoea-hypopnoea syndrome (OSAS), with mean respiratory disorder index
h71 (RDI) 601 (259) [in five associated with obesity-hypoventilation syndrome (OHS)]; two had central sleep
apnoea with mean RDI 45 (283) (one with hypothyroidism and one with cerebral multiple infarctions and right
hemidiaphragmatic paralysis) and two had OHS with mean RDI 125 (35). Noctumal hypoventilation was present
in almost all patients.
Continuous positive airway pressure (CPAP) was eective in three patients. Eight patients needed to be treated
with BILEVEL (BiPAP, Respironics Inc.) airway positive pressure in timed or spontaneous/timed modes. Two
patients required intubation and mechanical ventilatory treatment. In one patient with hypothyroidism was
sucient to institute hormonal therapy.
Our study shows that acute respiratory failure due to SRBD is not exceptional in an Intermediate Intensive Care
Unit and that if clinical suspicion is strong, portable polysomnography may yield diagnostic confirmation and help
in establishing appropriate treatment and in avoiding the invasive ventilatory treatment.
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In the majority of patients admitted with acute respiratory
failure (ARF) to an Intensive Care Unit an aetiology for
ARF is quite evident. However, in a minority of patients,
no obvious aetiology is apparent at presentation. Severe
obesity is still seldom considered as a potential cause forReceived 4 March 1999 and accepted 27 August 1999.
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0954-6111/00/020128+07 $35?00/0respiratory failure alone, and obstructive sleep apnoea per
se is rarely a cause for admission to an intensive care unit
(1). Thus sleep-related breathing disorder (SRBD) remains
infrequently diagnosed in patients with acute respiratory
failure, and a high index of suspicion is required to establish
the appropriate diagnosis, leading to the appropriated
treatment (2). The situation is further complicated because
the technology necessary for this type of diagnosis (i.e.
polysomnography) is usually unavailable in intensive care
units. Portable polysomnographic systems are available
nowadays, allowing for the recording of either a few# 2000 HARCOURT PUBLISHERS LTD
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graphic recording. Such systems may allow studying of
patients at home, but they may also be used to study
patients in the hospital, outside the sleep laboratory. Only a
few papers in the literature report on the initial diagnosis
and treatment of patients with undiagnosed SRBD in the
acute intensive care setting (2). The aim of the study was to
verify the utility of PSGp in a group of ARF intermediate
intensive care unit patients with a high suspicion of SRBD.
Moreover we evaluated if early and appropriate diagnosis
and treatment of the underlying problem may led to avoid
the invasive mechanical ventilation.
Material and methods
STUDY SUBJECTS
From a population of about 200 consecutive patients
admitted with respiratory failure to the Intermediate
Intensive Care Unit (IICU) of the University of Bari,
between September 1993 and November 1995, we selected
14 patients with unexplained ARF. The inclusion criteria
were:
(a) no clear aetiology of ARF at the presentation;
(b) a suggestive history of loud snoring and restless sleep,
excessive daytime sleepiness in the preceding months,
associated to a recent weight gain;
(c) obesity (BMI 4 30 kg m72) (3);
(d) no history of skeletal or neuromuscular or primitive
cardiovascular disease, no overt chronic lung diseases
such as chronic obstructive pulmonary disease
(COPD) in accordance with the ERS statement (4)
or obvious respiratory tract infections;
(e) no previous investigations for SRBD;
(f) no alcoholic, hypnotic or psycotropic drug
dependence.
On admission each patient underwent a detailed case
study and physical examination with particular attention to
signs and symptoms of heart failure and bronchopulmon-
ary diseases by portable chest roentgenogram, standard
electrocardiogram (ECG) and Doppler B-Mode echocar-
diography. Pulmonary functional tests were performed with
a pneumotachograph spirometer (Morgan system 306D,
Liverpool, U.K.) as soon as possible, when patients had
improved enough as to be able to cooperate with the testing.
MEASUREMENT OF SRBD
All patients underwent nightly PSGp (VITALOG HMS
500, Respironics Inc), while still resident in IICU, after a
period of 3–5 days.
We recorded alpha electroencephalographic activity,
electroculogram and chin electromyogram, oro-nasal air-
flow by thermocouples, thoracic and abdominal excursions
(respiratory inductive plethysmography), heart rate, snor-
ing sound, body position and oxygen saturation. Transcu-taneous CO2 was also recorded with a Radiometer
apparatus (Radiometer TC 100, Denmark).
In none of the patients did the polysomnographic studies
last less than 3 h.
During PSGp we scored obstructive (OA) or central
(CA) apnoeas defined as absence of airflow at the nose and
mouth for at least 10 sec, respectively with or without
respiratory eort; obstructive hypopnoea (OH) was defined
as a decrease in thoracic-abdominal amplitude, associated
with reduction of SaO2 of 4% for at least 10 sec; the
respiratory disorder index (RDI) was defined as the number
of apnoeas and hypopnoeas h71 of sleep. Hypoventilation
(HYP) was defined as non-apnoea associated desaturation
exceeding 45 sec associated with increasing level of
transcutaneous CO2 at least 7 mmHg; (09 kPa) (56).
All nocturnal studies were continuously followed by
expert physicians. To confirm the diagnosis of SRBD all
but one of the patients, repeated the nightly conventional
polysomnography (Respisomnographe Knightscan soft-
ware 180 version, Sefam, Nancy, France) in our sleep
laboratory at least 6 weeks after the episode of acute
cardiorespiratory failure. Sleep stage was scored by
standard criteria (7).
VENTILATORY TREATMENTS
When RDI was 15, SRBD was considered to be present
and treatment with CPAP and supplemental oxygen was
instituted during sleep. Pressure was progressively increased
under polysomnographic monitoring in 2 cmH2O incre-
ments to eliminate apnoeas, hypopnoeas and maintain
SaO2 4 88%. If CPAP failed, because of apnoeas and
hypopnoeas with significant oxygen desaturation persisted
despite the use of high pressure, or because of intolerance
or inability to ensure adequate ventilation, then nasal
ventilation was initiated with a BILEVEL device. Expira-
tory pressure was set at 4 cmH2O, and inspiratory pressure
at 10 cmH2O, and progressively increased in 20 cmH2O
steps. The device was used in the spontaneous, sponta-
neous/timed or timed mode, as needed. Ventilatory
assistance was always delivered trough a tightly fitted
nose-mask (Respironics Inc.) and, if necessary a chin strap
was added to minimize mouth leaks and ensure that
eective pressure was not lost. Criteria for intubation and
mechanical ventilation were clinical deterioration and either
a fall in pH below 710 or fall in arterial oxygen tension
(PaO2) with patient breathing by nasal mask to below
35 mmHg (47kPa) or when the patient was severely
obtunded.
To determine the home long-term ventilatory treatment,
before discharge we re-evaluated the patients’ current
response to CPAP or BILEVEL therapy. We used the
BIPAP ST Respironics Inc. device to deliver CPAP or
BILEVEL.
STATISTICAL ANALYSIS
Data are reported in the text and tables as mean (SD).
Statistical comparison were performed using the Student’
130 O. RESTA ET AL.test paired t-test with a P-value of less than 005 judged to
be statistically significant.
Results
The baseline data of 14 patients (eight males and six
females) are presented in Table 1. They had varying degrees
of acute respiratory failure, with pH ranging between 721
and 735, PaO2 ranging between 45 kPa and 67 kPa and
PaCO2 between 67 kPa and 124 kPa. Seven patients were
morbidly obese (BMI  40 kg m72).
Only two subjects showed evidence of moderate airflow
obstruction (patient 3 with forced expiratory volume on 1
sec (FEV1) forced vital capacity (FVC) of 58% and patient
8 with FEV1/FVC of 60%) with no chronic obstructive
pulmonary disease (COPD) history. Eight patients had
evidence suggesting a restrictive pattern (FVC 5 80% of
predicted, FEV1/FVC 4 70% predicted). Haemoglobin
concentration was  16 g dl71 in eight patients. All patients
had dyspnoea accompanied by altered mental status and
recent weight gain with marked leg oedema. Chest
roehentenogram in all patients revealed marked pulmonary
vascular congestion with bilateral pleural eusions in three
patients. Clinical signs, ECG and echocardiographic
evaluation suggested the presence of heart failure in 12/14
patients.
One patient presented anaemia due to gastric haemor-
rhage; three had Beta thalassemia; one had multi-brain
infraction and right hemidiaphragmatic paralysis; oneTABLE 1. Characteristics of the 14 patients on admission
Patient No. Age
years
Sex BMI
Kg m72
pH PaO
mmHg
1 80 f 33 721 43
2 34 m 37 732 48
3 70 m 36 721 40
4 51 f 55 735 46
5 50 m 64 732 49
6 46 m 48 735 50
7 65 m 36 724 38
8 62 f 32 729 36
9 70 f 43 731 47
10 62 m 52 727 41
11 50 m 40 729 35
12 38 m 50 725 36
13 60 f 38 728 46
14 62 f 34 728 34
MEAN 571 427 728 421
(SD) (129) (96) (004) (56)
BMI: body mass index; PaO2: arterial oxygen tension; PaCO2
FEV1: forced expiratory volume in 1 sec; % pred: percentagerevealed hypothyroidism. All patients received medical
treatment and weight loss.
PSGp was performed after 3 days in the IICU in six
subjects and after 5 days in the rest of patients. Significant
episodes of obstructive apnoeas and hypopnoeas were seen
in 10 patients whereas two patients showed episodes of
central apnoeas. Hypoventilation periods without apnoeas
or hypopnoeas were present in almost all patients, but
predominated as the main alteration in two patients.
Polysomnographic findings and final diagnosis were as
follows (Tables 2 and 3): 10 subjects had obstructive sleep
apnoea-hypopnoea syndrome (in five associated with
obesity-hypoventilation syndrome OHS); two patients had
central sleep apnoea (one with hypothyroidism and one
with cerebral multiple infractions and right hemidiaphrag-
matic paralysis) and two patients had OHS.
Treatment monitoring with PSGp showed that in three
patients CPAP was eective in relieving all abnormalities.
Eight patients needed to be treated with BILEVEL. In one
patient with hypothyroidism hormonal therapy was in-
stituted and the patient did well without the need to initiate
CPAP or assisted ventilation. Patient 3 and patient 5
required initially intubation and mechanical ventilation
because of pulmonary infection and deterioration of
respiratory failure, respectively.
All patients required supplemental oxygen initially
during ventilatory treatment with a resultant fractional
concentration in the inspiratory gas of 24–28%.
Patient 9 withdrew after 10 days. The mean hospitaliza-
tion stay of the remaining patients was 20 (SD 8) days. The
stay in hospital was longer in two patients who received2 PaCO2 FVC
% pred
FEV1/FVC
%
HGB
g dl71
kpa mmHg kpa
57 87 116 60 75 16
64 61 81 80 91 18
53 70 93 56 58 16
61 56 75 72 71 11
65 60 80 50 81 12
67 50 67 71 81 13
51 69 92 60 78 10
48 68 91 70 60 17
63 52 69 55 80 7
55 63 84 90 90 17
47 64 85 50 81 17
48 66 88 43 72 17
61 93 124 64 70 18
45 63 84 91 73 14
56 659 88 651 758 145
(07) (119) (16) (147) (95) (34)
: arterial carbon dioxide tension; FVC: forced vital capacity;
of predicted value; HGB: haemoglobin concentration.
TABLE 2. Polysomnographic findings for each subject studied
Patient
No.
SRBD RDI
n h71
NADIR
%
1 HYP OA 45 540
2 OA OH HYP 60 60
3 OA 25 65
4 OA HYP 65 540
5 OA OH HYP 96 63
6 OA HYP 80 70
7 OA HYP 55 60
8 HYP OA 55 58
9 HYP CA 25 80
10 OH 40 70
11 OA HYP 80 70
12 HYP 15 55
13 HYP 10 50
14 CA HYP 65 75
Mean 511 647
(SD) (259) (87)
SRBD: sleep related breathing disorders; RDI: respiratory disorder index; OA: obstructive apnoea; OH; obstructive
hypopnoea; CA: central apnoea; HYP: hypoventilation; NADIR: lowest nocturnal SaO2; n h
71: number h71.
TABLE 3. Final diagnosis and treatment for each subject studied
Patient No. Diagnosis Treatment
Mode IPAP cmH2O EPAP cmH2O
1 OSA BILEVEL T 20 8
2 OSA+OHS BILEVEL ST 18 8
3 OSA INTUB+VENT
4 OSA+OHS CPAP 14
5 OSA+OHS INTUB+VENT
6 OSA+OHS CPAP 12
7 OSA BILEVEL ST 24 10
8 OSA BILEVEL ST 22 6
9 CSA MEDICAL
10 OSH BILEVEL ST 14 6
11 OSA+OHS CPAP 11
12 OHS BILEVEL ST 20 4
13 OHS BILEVEL T 16 4
14 CSA BILEVEL T 20 4
OSA: obstructive sleep apnoea; OHS: obesity hypoventilation syndrome; OSH: obstructive sleep hyponoea;
CSA: central sleep apnoea; T: timed; ST: spontaneous/timed; IPAP: inspiratory positive airway pressure;
EPAP; expiratory positive airway pressure; INTUB+VENT: intubation and mechanical ventilation.
SLEEP RELATED BREATHING DISORDERS 131mechanical ventilation (mean 26 days). Eight patients were
discharged to their homes with CPAP and five with
BILEVEL nocturnal therapy indication. Twelve out of 14
were alive 32+6 months later.Figure 1 compares the blood gas values at admission and
at discharge for each individual patient. Mean PaO2
increased from 421 to 634 mmHg (56 to 85 kPa)
(P50001), mean PaCO2 decreased from 659 to 466 mmHg
132 O. RESTA ET AL.(88 to 62 kPa) (P50001) and mean pH increased from
728 to 738 (P50001). The SRBD diagnosis was
confirmed with conventional PSG in our sleep laboratory
following discharge (Table 4).
Discussion
We have found that acute respiratory failure due to SRBD
is not exceptional in the intermediate care unit and that if
clinical suspicion is strong, beside portable polygraphy may
yield diagnostic confirmation, help in establishing appro-
priate treatment and avoid the use of invasive mechanical
ventilation. Confirmation in the sleep laboratory with full
polysomnography may be obtained at a largest stage, when
the patient is in a stable condition. Moreover our studyTABLE 4. Polysomnographic data after discharge
Patient No. RDI n h71 TST min
1 30 301
2 51 325
3 23 331
4 51 287
5 77 300
6 77 280
7 40 290
8 44 302
9*
10 22 260
11 66 290
12 13 300
13 13 320
14 40 305
*missing. RDI: respiratory disorder index; TST: total sleep tim
NADIR: lowest nocturnal SaO2; OSA: obstructive sleep apnoe
sleep hypopnoea; CSA: central sleep apnea.
FIG. 1. Arterial blood gas data (PaO2, PaCO2 and pH) in
14 patients, at admission (A) compared to data at
discharge (D). Asterisks denote P50001.indicates that the nasal-mask ventilation can be safely
administered to SRBD patients with ARF.
In some patients admitted to ICU with a negative history
for skeletal or neuromuscular or cardiac or overt chronic
lung disease and with no respiratory tract infection, a
previously unrecognised SRBD may be the cause of the
ARF (2,8). The prevalence and the mechanism of ARF in
subjects with SRBD are not well known.
In our study from a population of about 200 patients
with respiratory failure referred to IICU over a 2 y period,
we selected 14 patients with ARF of no clear aetiology, but
with a high index of suspicion of SRBD (marked obesity,
loud snoring, excessive daytime sleepiness, progressive
dyspnoea unrelated to respiratory or cardiovascular dis-
eases) and in whom the polysomnographic study showed
the presence of SRBD. However this study does now allow
the evaluation of the prevalence of ARF in subjects with
SRBD and our data are only indicative. In the future we
need more prospective, controlled polysomnographic stu-
dies in a large group of patients with respiratory failure to
determine the clinical relevance.
In fact other studies have already scrutinized respiratory
complications caused by severe obesity (9) but few sleep
laboratories are currently studying this type of patient on a
regular basis and to our knowledge, PSG use in ICU or
IICU has rarely been reported (2).
In these patients some authors (2) have utilized conven-
tional PSG, performed while the patients are acutely ill and
others (8,1) once patient have been discharged home.
Although conventional PSG is the gold standard for sleep
study, it is an expensive and eort intensive procedure and
in some cases is not available. These limitations have led to
strategies aimed at including simple and portable record-
ings of nocturnal breathing into diagnosis of SRBD. InREM
%TST
NADIR % Diagnosis
72 70 OSA
121 72 OSA+OHS
120 70 OSA
78 50 OSA+OHS
63 72 OSA+OHS
80 77 OSA+OHS
62 71 OSA
68 66 OSA
88 88 OSH
73 80 OSA+OHS
86 55 OHS
88 60 OHS
70 75 CSA
e; REM: rapid eye movement sleep;
a; OHS: obesity hypoventilation syndrome; OSH: obstructive
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diagnostic purposes and it’s quite sucient to confine the
registration to respiratory parameters (10). In this study, we
utilized VITALOG HMS 5000 Pocket Polygraph (Respiro-
nics Inc.), a 10 channels record portable system previously
validated (11). It allows a simplified representation of sleep
structure [rapid eye movement (REM) non-REM], permit-
ting verification of the total sleep time and monitoring of
the outcome of respiratory disorders.
Furthermore the PSGp allowed us to diagnose and
predict outcome in patients in IICU in a simple, ecacious
and cheap way, avoiding the diculties associated with
transport in a sleep laboratory. Subsequently, we per-
formed conventional PSG in our sleep laboratory which
confirmed in all patients the diagnosis obtained with PSGp.
Early and correct recognition of ARF related to SRBD
in these patients was essential for instituting appropriate
ventilatory treatment and, by controlling the nightly
respiratory disorders, improving daytime ventilatory func-
tion, reversing RF and avoiding unnecessary procedures.
It is unclear why ARF with varying degrees develops in
some patients with SRBD and not in other. Reduced or
defective response of both hypercapnia or hypoxaemia
identified many years ago in subjects with OHS (12), and
abnormality in mechanical properties of the chest wall
associated with obesity (13,14), have been put forward to
explain the occurrence of respiratory failure in this type of
patient.
All patients in our study were obese; seven were grossly
obese (BMI  40 kg m72) and half had OHS. Some studies
in the past have been devoted to OHS but diagnosis, as in
our experience, was often made in the case of acute
cardiopulmonary failure episodes (15,16). Obstructive
apnoeas or hypopnoeas observed in the majority of these
subjects may be absent and sustained hypoventilation
events uncorrected by CPAP, may be the only night
abnormality and contribute to daytime hypercapnia. In
addition to obstructive or central apnoeas, 12 patients of
our group, presented nightly impairment of awake hypo-
ventilation, more or less severe and in five patients (two
with OHS, two with OSA and one with CSA) hypoventila-
tion was the sole or the predominant SRBD. According to
Piper et al. (17) we showed that the awake hypoventilation
was reversed or reduced in these subjects with eective
control of sleep respiratory disorders.
Although CPAP is a generally accepted and utilized as
the treatment of choice for OSA, in patients with extreme
upper airway narrowing that exceeds the ability of CPAP to
maintain airway patency or in OSA associated with
decompensated respiratory failure and marked hypoventi-
lation or with unacceptable high levels of CO2 retention
during CPAP therapy, BILEVEL positive airway pressure
(1,18,19,20) have been used with favourable results. Our
study confirms that non invasive ventilation can be free of
problems and can be ecacious and well tolerated in
patients with ARF related to SRBD. In fact, in our study
all but two of the subjects avoid endotracheal intubation,
invasive mechanical ventilation and tracheotomy. Avoiding
endothracheal intubation and mechanical ventilation in
these patients can spare a prolonged period of weaning andthe complication due to tracheostomy (21). Non-invasive
treatment modality fell into three categories: CPAP,
BILEVEL and (in one patient) hormonal therapy. The
majority of our patients during ARF failed to respond
initial CPAP therapy and required nasal ventilation with
BILEVEL in S/T or T mode. In these patients CPAP was
ineective (persistence or emergency of hypoventilation or
presence of CA) or not well tolerated for the unacceptable
level of pressure. However according to Piper et al. (17)
when ventilatory decompensation was reversed was possi-
ble to transfer most patients back to CPAP therapy for
home long-term treatment.
Our report confirms that SRBD is thought to be the
cause of ARF in some patients admitted to the IICU,
especially if grossly obese and with a suggestive history. In
these patients a sleep study should be performed in order to
diagnose a previously unrecognized SRBD following the
ventilatory treatment. In addition our data, although
limited and preliminary, show that PSGp in expert hands
is feasible and ecacious method of studying the acutely ill
IICU patients and can avoid the diculties associated with
transport in a sleep laboratory.
Early and correct recognition of SRBD in these acutely
ill patients may lead to institution of the appropriate
ventilatory management and to a decrease in unnecessary
procedures such as tracheotomy and prolongent mechan-
ical ventilation. The latter, however, requires additional
prospective, controlled clinical studies and a larger group of
patients.
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